Abstract:Amides with beta-carboxylic acid groups are stable and negatively charged at physiological pH, but hydrolyze back to the corresponding amines and anhydrides once in an acidic environment. We thereby developed charge-reversal nanocarriers for drug delivery. In these systems, the anhydrides served only as groups to amidize the amines in cationic polymers and had no therapeutic use after being cleaved from the carrier in the cells. Herein, we utilized the characteristic anhydride structure of norcantharidin (NCTD) and the pH-dependent hydrolysis of its beta-carboxylic amides and developed novel acid-labile conjugates for the targeted delivery of NCTD. In this study, NCTD was used as both an anticancer drug and an acid-labile anhydride to react with cationic polymers including PEI and PLL to form beta-carboxylic amides. The obtained conjugates (PEI-NCTD and PLL-NCTD) had not only significantly improved NCTD solubility and high drug loading contents (as high as 72.3% and 56.8%, respectively, for PEI-NCTD and PLL-NCTD), but also favorable acid-labile capabilities. These conjugates were stable and negatively charged at neutral pH, but once in acidic environments (e. g. endo/lysosomes), they hydrolyzed and regenerated not only NCTD as an antitumor drug, but also the PEI or PLL, which could assist the endo/lysosomal escape and release of the drugs. Further, functionalizing the acid-labile conjugates with targeting moiety folic acid (FA) increased the cellular uptake of the conjugates into folate receptor-overexpressing tumor cells and thereby the in vitro cytotoxicity. These targeted acid-labile conjugates may help to reduce the side effects of NCTD and improve its clinical applications.

Targeted Charge‐Reversal Nanoparticles for Nuclear Drug Delivery

Targeted Charge-Reversal Nanocarriers for Nuclear Drug Delivery

Linear polyethyleneimine-based charge-reversal nanoparticles for nuclear-targeted drug delivery

Charge‐Reversal Drug Conjugate for Targeted Cancer Cell Nuclear Drug Delivery

Charge-reversal nanoparticles: novel targeted drug delivery carriers

Charge-reversal polyamidoamine dendrimer for cascade nuclear drug delivery.

Ph and Charge Reversal-Driven Nanoplatform for Efficient Delivery of Therapeutics.

Charge-reversal nanocarriers: An emerging paradigm for smart cancer nanomedicine

Magnetically Controllable Polymer Nanotubes from a Cyclized Crosslinker for Site-Specific Delivery of Doxorubicin

Surface charge-reversible polyelectrolyte complex nanoparticles for hepatoma-targeting delivery of doxorubicin.

Ph-Activated Size Reduction of Large Compound Nanoparticles for in Vivo Nucleus-Targeted Drug Delivery.

Reversion of Ph-Induced Physiological Drug Resistance: A Novel Function of Copolymeric Nanoparticles

Targeted acid-labile conjugates of norcantharidin for cancer chemotherapy

A C5N2 Nanoparticles-Based Direct Nucleus Delivery Platform for Synergistic Cancer Therapy.

Nir/Ph Dual-Sensitive Polypeptide Nanocomposite Charge-Reverse, Generates No for Triple-Combination Therapy to Reverse Cancer Multidrug Resistance

Acidity-Activated Charge Conversion of 177 Lu-Labeled Nanoagent for the Enhanced Photodynamic Radionuclide Therapy of Cancer

Zwitterionic-to-cationic Charge Conversion Polyprodrug Nanomedicine for Enhanced Drug Delivery.

Mechanisms, Challenges, and Therapeutic Applications

Breast Cancer-Targeted Nuclear Drug Delivery Overcoming Drug Resistance for Breast Cancer Chemotherapy

Light-controllable Charge-Reversal Nanoparticles with Polyinosinic-Polycytidylic Acid for Enhancing Immunotherapy of Triple Negative Breast Cancer.

Charge-reversible crosslinked nanoparticle for pro-apoptotic peptide delivery and synergistic photodynamic cancer therapy